Ceftazidime Dosing for Newborns
For neonates 0-4 weeks of age, administer ceftazidime 30 mg/kg IV every 12 hours, with dosing intervals adjusted based on gestational age and postnatal age. 1
Age and Gestational Age-Based Dosing Algorithm
The dosing of ceftazidime in newborns must account for both gestational age (GA) and postnatal age (PNA) due to immature renal function affecting drug clearance:
For Premature Infants (GA <32 weeks):
- Postnatal age <14 days: 50 mg/kg IV every 12 hours
- Postnatal age ≥14 days: 50 mg/kg IV every 8 hours 2
For Term and Near-Term Infants (GA ≥32 weeks):
- Postnatal age ≤7 days: 50 mg/kg IV every 12 hours
- Postnatal age >7 days: 50 mg/kg IV every 8 hours 2
FDA-Approved Dosing (Simplified):
- All neonates 0-4 weeks: 30 mg/kg IV every 12 hours 1
Key Clinical Considerations
The higher doses (50 mg/kg) from the pediatric MDRO guidelines 2 are specifically for multidrug-resistant organisms and serious infections, while the FDA label provides a more conservative general dosing recommendation of 30 mg/kg every 12 hours 1. The choice depends on infection severity and suspected pathogen.
Pharmacokinetic Rationale:
- Elimination half-life in neonates ranges from 2.9 to 6.7 hours (compared to 1.9 hours in adults), varying inversely with gestational age 3
- Younger, more premature infants have prolonged half-lives requiring longer dosing intervals 4
- Ceftazidime is eliminated almost entirely by glomerular filtration, making renal maturity the critical determinant 1
For Serious Pseudomonas Infections:
When treating serious Pseudomonas infections in neonates with normal renal function, doses up to 30-50 mg/kg IV every 8 hours may be used, with a maximum of 6 grams per day 1. This higher dosing is supported by pharmacokinetic-pharmacodynamic modeling showing that more aggressive dosing may be needed for late-onset sepsis in term infants 5.
Critical Pitfalls to Avoid
Do not use adult dosing intervals in neonates—the prolonged half-life in this population necessitates less frequent dosing to prevent accumulation and neurotoxicity 6.
Renal function monitoring is essential: Even in neonates without overt renal disease, immature kidney function affects clearance. If renal impairment is suspected, further dose reduction or interval extension is required 1.
Avoid underdosing in late-onset sepsis: Recent population PK data suggests that for neonates >3 days old with suspected resistant organisms (MIC ≥8-16 mg/L), the standard 30 mg/kg every 12 hours may be insufficient, and doses of 30-40 mg/kg every 8 hours should be considered 5.
Therapeutic Drug Monitoring:
While not routinely performed, trough concentrations should remain well below the neurotoxicity threshold of 78 mg/L 6, particularly in premature infants with reduced clearance.